Executive Summary
Neuropharm Group plc is a speciality pharmaceutical group focused on the development of drugs for the treatment and management of selected developmental and degenerative disorders. The Group's vision is to be a partner of choice for clinicians and patient organisations working in the field of Central Nervous System (\CNS\) disorders and to develop effective therapies which offer significant benefits for physicians, healthcare providers and patients alike. The Group's lead programme is based upon obtaining regulatory approval for a new indication for fluoxetine targeting the core symptomatology in Autism.
Company History
Current Events
Business Model
Products/Services
Segments/Customers
Production/Operations
Distribution/Routes to Market
Market & Competition
Market Share
Main Competitors
Competitive Strengths and Weaknesses
Management
Financials
Profit & Loss
Balance sheet
Cashflow
Valuation
Comparable Companies
SWOT Analysis
Strengths
Weaknesses
Opportunities
Threats
